Pages

Monday, April 29, 2013

Seeking Alpha: Illumina Flexes Its Muscles A Bit

The strong revenue growth and lucrative margins of Illumina's (ILMN)
core sequencing business has attracted ample competition over the
years. It's testament to the quality of Illumina's technology (both
acquired and internally-developed), though that a lot of these
competitive attempts have only served to highlight the attributes and
advantages of the company's approach.

I certainly have my
questions and doubts about Illumina. I do think the company was caught a
little flat-footed by the success of Life Technologies' (LIFE)
Ion Torrent products, and my talks with several people in
academic/research labs do lead me to believe they rushed their
high-throughput products to market (leading to some unhappy customers).
Last and not least, I think that Street expectations for
sequencing-driven clinical diagnostics could be ambitious. All of that
said, though, it's hard not to acknowledge and appreciate the business
that Illumina is building here.

No comments:

Search This Blog

About Me

I started this blog as a way of archiving my writing for sites like Investopedia, as well as posting some thoughts on the markets, stocks, or whatever else strikes my fancy.
Feel free to email me.
You can reach me at tuonela (dot) fool (at) gmail (dot) com

Get My Articles Delivered By Email

Followers

Subscribe To

Disclaimer

This blog represents the opinions and views of its author.

Information is taken from sources believed to be reliable but no warranty or guarantee is made with respect to accuracy.

Investing involves risk and requires proper due diligence. In no way should a reader should presume this blog represents personalized financial advice or is a substitute for proper due diligence. The author expects you to be enough of a grown-up to realize this.